Prior miscarriage and antinuclear antibody positivity are independent risk factors associated with adverse pregnancy outcomes among women with rheumatoid arthritis (RA).
Antinuclear antibody (ANA) positivity and history of miscarriage are both independent risk factors for adverse pregnancy outcomes (APOs) among women with rheumatoid arthritis (RA), according to a study published in Clinical Rheumatology.
The study also found that APOs and low-dose prednisone have no effect on the health of the child, though there is no clear consensus on this relationship.
To come to these findings, the study authors included 67 pregnant women with RA who were hospitalized between January 2007 and September 2021 in the Department of Obstetrics at Peking University People’s Hospital in China.
Women with RA are at higher risk of experiencing APOs, such as preterm delivery, low birth weight, small for gestational age infants, or preeclampsia, compared with pregnant women without RA, the authors explained. Additionally, high RA disease activity and the use of prednisone during pregnancy are both associated with increased APO risk in this group.
The participants were seen at least once per trimester and after delivery to evaluate any associations between RA disease activity, medication use, and pregnancy outcomes. Data on RA disease activity and fetal outcomes were collected from medical records.
Of the 67 women in the cohort, 29 (43.3%) experienced an APO, with the most common pregnancy complications being postpartum hemorrhage (20.9%) and premature delivery (11.9%).
The 2 risk factors for APOs identified in the study were previous miscarriages (OR, 1.869; 95% CI, 1.053-3.318, P = .033) and ANA positivity (OR, 3.168; 95% CI, 1.068-9.768, P = .045).
The RA disease activity remission rate during pregnancy was higher in women without APOs compared with women who did experience APOs (P = .027), however there were no significant differences between these 2 groups regarding daily and cumulative prednisone doses (P > .05).
According to the authors, the reason for disease remission during pregnancy is still unclear, even when accounting for hormonal changes and immunological alterations during pregnancy. They also noted that some studies found a link between remission and galactosylation.
“In the context of inflammatory joint disease, there is no significant improvement in disease activity during pregnancy, as 43.3% of patients showed worsening of arthritis during pregnancy in our study, and more than half of RA patients showed worsening of arthritis after delivery in another study,” the authors write.
The study also included a total of 71 fetuses of these women. Of this group, 2 fetuses were aborted, 2 were delivered by induced labor due to chromosomal abnormality, and 1 died in utero. The children of the participants were followed up with, and long-term follow-up showed no significant differences in the children’s health between women who did and did not experience APOs (P > .05).
According to the authors, these findings suggest ANA is a potential biomarker for predicting APOs in women with RA, further suggesting all patients with RA should be screened for ANA beforehand if they wish to become pregnant.
The authors noted that the small sample size is a major limitation of the study, especially due to the fact that RA onset is typically past the childbearing age.
Reference
Luo L, Li X, Yan R, Zhang H, Li C. Risk factors for adverse pregnancy outcomes in women with rheumatoid arthritis and follow-up of their offspring. Clin Rheumatol. Published online June 13, 2022. doi:10.1007/s10067-022-06233-9
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More